Analysis: Genentech Positioned for Unimpeded Growth

June 17, 2005 -- You've seen the news: Genentech is buying Biogen Idec's Tysabri plant in Oceanside, California, for $408 million. This is very significant for Genentech because it brings on a huge increase in capacity -- sooner and cheaper than they could have done it themselves. This has to be one of the best all-time bargains in biotech manufacturing capacity. We look at why this is such a good deal, one that also solves a big problem for Genentech...

Back to news